Last reviewed · How we verify
NCT07132957
A Study of AL8326 in Healthy Subjects
Phase 1 trial testing 14C-labeled AL8326 in Small Cell Lung Cancer in 6 participants. Completed in 17 May 2025.
17 May 2025
Quick facts
| Lead sponsor | Advenchen Laboratories Nanjing Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 6 |
| Start date | 21 February 2025 |
| Primary completion | 17 May 2025 |
| Estimated completion | 17 May 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- 14C-labeled AL8326 — full drug profile →
Conditions studied
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
- Solid Tumors — all drugs for Solid Tumors →
Sponsor
Advenchen Laboratories Nanjing Ltd. — full company profile →
Who can join
Adults 18 to 45, male only, with Small Cell Lung Cancer or Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard. On the first day of the experiment, each subject orally took a single dose of \[14C\] AL8326 oral formulation containing approximately 60mg (200 μ Ci). During the experiment, whole blood, plasma, urine, and fecal samples were collected at designated time points/time periods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07132957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
- NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting
Other Advenchen Laboratories Nanjing Ltd. trials
Trials by the same sponsor.
- NCT07438886 — Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07179081 — A Study of AL58805 in Patients With Advanced Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07132957 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Advenchen Laboratories Nanjing Ltd.
- Last refreshed: 20 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07132957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing